Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Illustration of a blue jay flying away into the sunset

Gene therapy

Bye Bye Bluebird: Gene Therapy Biotech Emerges From Private Buyout With Rebrand

Bluebird bio has re-emerged after a private equity buyout as Genetix Biotherapeutics, marking a return to its roots and a new path forward for manufacturing.

September 19, 2025

2 min read

Annalee Armstrong

Close-Up Of Syringe With Bottles Against Blue Background

Vaccines

Reformed ACIP Recommends Delaying MMRV Combo Vaccination, Forecasts Changes to Hep B, COVID

BMO Capital Markets analysts said the first day of the CDC vaccine advisory committee meeting Thursday had anti-vaccine overtones as the panel, which was revamped by Health Secretary Robert F. Kennedy, Jr. in June, voted to recommend that children under four receive the measles, mumps, rubella (MMR) vaccine separately from a chickenpox vaccine. Today the advisors will vote on changing the childhood schedule for the hepatitis B and COVID-19 vaccines.

September 19, 2025

2 min read

Tristan Manalac

Problems and Challenges. Businessman stands on question mark

Immuno-oncology

Replimune Crashes as Uncertainty Clouds Regulatory Path for Tumor Destroyer

Investors had been “holding out hope” that there remained a regulatory path forward for RP1, but results of Replimune’s Type A meeting with the FDA do not appear to support this, according to BMO Capital Markets.

September 19, 2025

2 min read

Tristan Manalac

External view of the U.S. Capitol building

Rare diseases

Hope for Rare Pediatric Disease Voucher Reignited as House Bill Passes Committee

The House Committee on Energy and Commerce has cleared proposed legislation that could bring back the FDA’s rare pediatric priority review voucher program, which allows for expedited drug reviews.

September 19, 2025

2 min read

Tristan Manalac

Creative trend collage of hand take education read book pile programmer coding studying billboard comics zine minimal.

Immunology and inflammation

Nektar Provides More Data for Dermatitis Drug, but Key Questions Remain Unanswered

Nektar Therapeutics still needs to establish what differentiates rezpeg from other atopic dermatitis therapies, according to analysts at William Blair.

September 19, 2025

2 min read

Tristan Manalac

Contemporary art collage of people, employees carrying geometric figures symbolizing team work. Concept of team, business, success, professional growth, career, analytics. Copy space for ad

Neurodegenerative disease

VectorY Bets up to $1.2B+ That Shape’s Brain-Penetrant Capsids Are a Fit

VectorY Therapeutics will evaluate the use of SHP-DB1, a capsid developed by Shape Therapeutics, to deliver therapies to the brain, including VectorY’s developmental Huntington’s and Alzheimer’s disease treatments.

September 18, 2025

2 min read

Dan Samorodnitsky

Layoffs

Layoffs From Just 6 Pharmas Could Wipe Out Over 39,000 Jobs

This year, Novo Nordisk and Merck announced significant layoffs, with Novo planning to axe about 9,000 employees and Merck projecting it could let go of roughly 6,000. Meanwhile, Bayer, Bristol Myers Squibb, Novartis and Pfizer have also made noteworthy cuts.

September 18, 2025

9 min read

Angela Gabriel

PODCAST

What Do AI and Hammers Have in Common?

In this episode of Denatured, BioSpace’s head of insights Lori Ellis and Colin Zick, partner at Foley Hoag LLP, spend time discussing some of the points brought up in the Bioprocessing Summit last month. They explore the connections between hammers, AI, The Planet of the Apes and monoliths.

September 18, 2025

1 min read

Lori Ellis